Larry Anderson, MD, PhD
Larry Anderson is Associate Professor in University of Texas (UT) Southwestern Medical Center’s Department of Internal Medicine, Division of Hematology/Oncology.
Dr. Anderson earned both a medical degree from the University of Texas Medical School at Houston and a doctoral degree in immunology from MD Anderson Cancer Center and the UT Graduate School of Biomedical Sciences/Health Science Center at Houston. He completed an internship and residency in internal medicine at the Mayo Clinic’s Graduate School of Medicine, followed by a fellowship in medical oncology at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center.
Dr. Anderson treats plasma cell disorders that include multiple myeloma, Waldenström’s macroglobulinemia, amyloidosis, and other gammopathies. He specializes in treating these diseases with bone marrow transplantation. He is also happy to see plasma cell disorder patients for second opinions to help with guiding treatment decisions, getting them on new therapies on clinical trials, or just for their stem cell transplant process, after which they can return to their referring oncologist if they like.
Dr. Anderson’s research interests include cancer immunology, immunotherapy, multiple myeloma, and stem cell transplantation. His research has been funded by the American Cancer Society, National Institutes of Health, American Society of Clinical Oncology, and the Multiple Myeloma Research Foundation.
Representative Publications:
Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate GVHD and increases PERI-BMT mortality
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer’s disease as it diminishes antigen-specific Th1 and Th17 cell proliferation
Adoptive T-cell therapy for B-cell malignancies
Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect
